27 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
20 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2022 LungLife to report financial results for full-year 2022 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2022. Summary and Highlights […]
LungLife AI licensure/accreditation information posted here.